论著

卵巢囊性腺纤维瘤和卵巢腺纤维瘤的超声诊断效能及图像特征分析

展开
  • 上海交通大学医学院附属瑞金医院妇产科,上海 200025

收稿日期: 2021-01-29

  网络出版日期: 2022-06-28

基金资助

上海市科委医学创新研究项目(20Y11914000)

The ultrasonic features and diagnostic performance of ultrasound for ovarian cystadenofibroma and adenofibroma

Expand
  • Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2021-01-29

  Online published: 2022-06-28

摘要

目的:探讨卵巢囊性腺纤维瘤(cystadenofibroma,CAF)和卵巢腺纤维瘤(adenofibroma,AF)的超声图像特征。方法:回顾性分析经术后病理检查证实的50例卵巢CAF和7例卵巢AF患者的超声声像图特征,并评估超声的诊断价值。结果:根据病理结果,50例CAF中,良性为46例,共47个肿块;交界性为4例,均为单发,7例AF均为良性单发病灶。卵巢CAF和AF的病理分型以浆液性为主(53/58,91.4%)。将交界性肿瘤归入恶性肿瘤,术前超声检查鉴别CAF及AF肿块良恶性的灵敏度为100.0%[95%置信区间(confidential interval,95%CI)为39.8%~100.0%],特异度为72.2%(95%CI为58.4%~83.5%),准确率为74.1%。超声图像上,良性CAF多表现为形态规则(43/47,91.5%)、边界清晰(46/47,97.9%)的单房囊实性肿块(25/47,53.2%),且多数肿块附壁有规则的乳头状突起(32/47,68.1%),突起内无或少量血流信号(31/32,96.9%)。交界性CAF的超声表现均有实性部分或乳头状突起,内部血供程度为少量至丰富不等。与良性CAF相比,交界性CAF实性部分或乳头状突起的最大径更大[最大径,19.5(18.8~26.3) mm比8.0(7.0~13.0) mm,P=0.002],实性部分或乳头状突起与肿块最大径比值更大(0.35比0.15,P=0.033),内有血供者更多(4/4比10/35,P=0.012)。AF超声图像多表现为形态规则(6/7)、边界清晰(5/7)且后方伴有回声衰减的实性肿块(4/7),其实性部分内呈乏血供表现(6/6)。结论:超声诊断CAF及AF的效能一般。良性CAF多表现为附壁有乏血供乳头状突起的囊实性肿块;交界性CAF多表现为有不同程度血供的实性或乳头状突起的肿块;而AF多表现为后方伴回声衰减、无血供的实性肿块。肿块在超声图像上表现为实性成分多和血供程度丰富,多提示交界性CAF。

本文引用格式

钱乐, 姜美娇, 杨伯文, 陈慧 . 卵巢囊性腺纤维瘤和卵巢腺纤维瘤的超声诊断效能及图像特征分析[J]. 诊断学理论与实践, 2021 , 20(02) : 161 -167 . DOI: 10.16150/j.1671-2870.2021.02.008

Abstract

Objective: To investigate ultrasonic features of ovarian cystadenofibroma (CAF) and adenofibroma (AF). Methods: Ultrasonic features of 50 cases with ovarian CAF and 7 cases with AF were analyzed, and diagnostic performance of ultrasound was evaluated. Results: According to pathological findings of the CAF cases studied, 46 were benign CAF with 47 tumors identified, and 4 cases were borderline AF. All the seven AF cases were benign with single lesion. Pathologically, most of lesions was serous (53/58, 91.4%). With borderline CAF defined as malignant, the ultrasound differentiated benign from malignant masses of CAF and AF with a sensitivity of 100.0% (95%CI 39.8%-100.0%), specificity of 72.2% (95%CI 58.4%-83.5%), and accuracy of 74.1%. Most benign CAF masses were described as unilocular solid cysts (25/47, 53.2%) with regular morphology (43/47, 91.5%) and well-defined boundaries (46/47, 97.9%). Regular papillary projections (32/47, 68.1%) in CAF lesions manifested no or minimal color Doppler signals(31/32, 96.9%). The borderline CAF masses were all identified with solid components or papillary projections, which manifested various degree of blood supply. Compared with benign CAF, borderline CAF showed more solid or papillary components [maximum diameter, borderline CAF was 19.5 (18.8-26.3) mm versus benign 8.0 (7.0-13) mm, P=0.002], with higher the maximum diameter ratio of the solid components or papillary projections to the mass [the borderline CAF was 0.35 versus benign CAF 0.15, P=0.033], and there were more blood supply inside the borderline CAF (4/4) than benign CAF (10/35), (P=0.012). Most of the AF masses were described as regular (6/7), well-defined (5/7) solid masses with shadowing identified (4/7). Absent color Doppler signals were recorded in the solid components (6/6). Conclusions: The ultrasound has a sound diagnostic performance for CAF and AF. Benign CAF lesions are mostly described as solid cysts with papillary projection(s) manifesting no or minimal color Doppler signals; borderline CAFs are mostly described as masses with papillary projection(s) and solid component(s) containing varied blood supply. AFs are mostly described as solid masses with shadowing identified and absent color Doppler signals. It is difficult to discriminate benign from borderline CAF, presence of solid components or papillary projections and copious blood supply may indicate borderline CAF.

参考文献

[1] Taylor EC, Irshaid L, Mathur M. Multimodality imaging approach to ovarian neoplasms with pathologic correlation[J]. Radiographics, 2021, 41(1):289-315.
[2] Cho SM, Byun JY, Rha SE, et al. CT and MRI findings of cystadenofibromas of the ovary[J]. Eur Radiol, 2004, 14(5):798-804.
[3] Czernobilsky B, Borenstein R, Lancet M. Cystadenofibroma of the ovary. A clinicopathologic study of 34 cases and comparison with serous cystadenoma[J]. Cancer, 1974, 34(6):1971-1981.
[4] Kozawa E, Inoue K, Takahashi M, et al. Diffusion-weighted MR imaging findings of ovarian adenocarcinofibromas and adenofibromas[J]. Clin Imaging, 2014, 38(4):483-489.
[5] Timmerman D, Valentin L, Bourne TH, et al. Terms, de-finitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis(IOTA) Group[J]. Ultrasound Obstet Gynecol, 2000, 16(5):500-505.
[6] Andreotti RF, Timmerman D, Strachowski LM, et al. ORADS US risk stratification and management system: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee[J]. Radiology, 2020, 294(1):168-185.
[7] Tang YZ, Liyanage S, Narayanan P, et al. The MRI features of histologically proven ovarian cystadenofibromas-an assessment of the morphological and enhancement patterns[J]. Eur Radiol, 2013, 23(1):48-56.
[8] 潘玉萍, 蔡爱露, 赵丹, 等. 卵巢腺纤维瘤及囊性腺纤维瘤的超声特征[J]. 中国医学影像技术, 2012, 28(9):1699-1701.
[9] Shimizu S, Okano H, Ishitani K, et al. Ovarian cystadenofibroma with solid nodular components masqueraded as ovarian cancer[J]. Arch Gynecol Obstet, 2009, 279(5):709-711.
[10] 徐健, 梅海炳, 高军, 等. 卵巢浆液性囊性腺纤维瘤MR诊断及病理分析[J]. 医学影像学杂志, 2016, 26(8):1494-1497.
[11] Virgilio BA, de Blasis I, Sladkevicius P, et al. Imaging in gynecological disease(16): clinical and ultrasound cha-racteristics of serous cystadenofibromas in adnexa[J]. Ultrasound Obstet Gynecol, 2019, 54(6):823-830.
[12] Goldstein SR, Timor-Tritsch IE, Monteagudo A, et al. Cystadenofibromas: can transvaginal ultrasound appea-rance reduce some surgical interventions?[J]. J Clin Ultrasound, 2015, 43(6):393-396.
[13] Landolfo C, Valentin L, Franchi D, et al. Differences in ultrasound features of papillations in unilocular-solid adnexal cysts: a retrospective international multicenter study[J]. Ultrasound Obstet Gynecol, 2018, 52(2):269-278.
[14] Timor-Tritsch IE, Yoon E, Monteagudo A, et al. Ultrasound and histopathologic correlation of ovarian cystadenofibromas: diagnostic value of the “shadow sign”[J]. J Ultrasound Med, 2019, 38(11):2973-2978.
[15] Zheng X, Lyu G, Gan Y, et al. Microcystic pattern and shadowing are independent predictors of ovarian borderline tumors and cystadenofibromas in ultrasound[J]. Eur Radiol, 2021, 31(1):45-54.
[16] Takeuchi M, Matsuzaki K, Harada M. Ovarian adenofibromas and cystadenofibromas: magnetic resonance ima-ging findings including diffusion-weighted imaging[J]. Acta Radiol, 2013, 54(2):231-236.
[17] Jung DC, Kim SH, Kim SH. MR imaging findings of ovarian cystadenofibroma and cystadenocarcinofibroma: clues for the differential diagnosis[J]. Korean J Radiol, 2006, 7(3):199-204.
[18] 顾海磊, 唐文伟, 田忠甫, 等. 卵巢(囊)腺纤维瘤的磁共振成像诊断及鉴别[J]. 实用放射学杂志, 2020, 36(11):1798-1801.
[19] Chen H, Liu Y, Shen LF, et al. Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison[J]. J Ovarian Res, 2016, 9(1):81.
[20] Zhang Z, Wu Y, Gao J. CT diagnosis in the thecoma-fibroma group of the ovarian stromal tumors[J]. Cell Biochem Biophys, 2015, 71(2):937-943.
[21] 张慧娟. 卵巢交界性腺纤维瘤及囊腺纤维瘤的病理诊断[J]. 实用妇产科杂志, 2005, 21(10):586-588.
文章导航

/